scholarly journals Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate

2021 ◽  
Author(s):  
Akira Oshima ◽  
Teruhiko Imamura ◽  
Nikhil Narang ◽  
Koichiro Kinugawa
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Sodium Zirconium ◽  
Sodium Zirconium Cyclosilicate

P0200KEEP ON (KEEPING RAAS INHIBITION TREATMENT WITH OPTIMAL POTASSIUM CONTROL). DESIGN OF A CLINICAL TRIAL OF USING SODIUM ZIRCONIUM CYCLOSILICATE FOR KEEPING RAAS INHIBITION AND/OR MRAS IN PATIENTS WITH CKD AND CONGESTIVE HEART FAILURE HISTORY

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Maria Jesãºs Puchades Montesa ◽  
Nayara Panizo Gonzalez ◽  
Luis D'Marco ◽  
Miguel Gonzalez-Rico ◽  
Patricia Tomas ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cardiorenal Syndrome ◽  
Serum Electrolytes ◽  
Sodium Zirconium ◽  
Multifrequency Bioimpedance ◽  
Threatening Condition ◽  
Life Threatening ◽  
Sodium Zirconium Cyclosilicate ◽  
Nephroprotective Effect

Abstract Background and Aims Hyperkalemia (HK) is a potentially life-threatening condition, in patients with chronic kidney disease (CKD) and congestive heart failure (CHF). The majority of patients affected with CKD or CHF, must be treated with inhibitors of renin angiotensin aldosterone system (RAASi) and mineralocorticoid receptor antagonists (MRAs). However, the treatments previously mentioned, increase the risk of HK episodes, which is the main cause of RAASi and MRAs downtitration or discontinuation, representing an undesirable clinical scenario, given that the patients are at high risk of be deprived of their nephroprotective effect and cardio-renal benefits The aim of the study is: to analyze if, in patients with HK, CKD and CHF treated with RAASi and/or MRA, serum potassium (sK) reduction by Sodium zirconium cyclosilicate (SZC) treatment is non-inferior to RAASi and/or MRAs discontinuation or downtitration. Method Results The study will demonstrate results on serum electrolytes, renal function, albuminuria, KDQoL questionnaire and changes in relative overhydration (multifrequency bioimpedance -BCM Fresenius-) Conclusion The KEEP ON study will define the ability of SZC to facilitate the use of RAAS-I and / or MRA in patients with HK and cardiorenal syndrome allowing the maintenance of the medications recommended by international guidelines for the treatment of CHF at different degrees of CKD while maintaining the potential cardio-renal and nephroprotective benefit.

scholarly journals Hyperkalaemia in Heart Failure

2021 ◽  
Vol 7 ◽  
Author(s):  
Umar Ismail ◽  
Kiran Sidhu ◽  
Shelley Zieroth
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Medical Therapy ◽  
Renin Angiotensin Aldosterone System ◽  
Sodium Zirconium ◽  
Patients With Heart Failure ◽  
Raas Inhibitors ◽  
Potassium Binding ◽  
Sodium Zirconium Cyclosilicate

Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.

scholarly journals Maintenance of serum potassium with sodium zirconium cyclosilicate ( ZS ‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial

2015 ◽  
Vol 17 (10) ◽  
pp. 1050-1056 ◽  
Author(s):  
Stefan D. Anker ◽  
Mikhail Kosiborod ◽  
Faiez Zannad ◽  
Ileana L. Piña ◽  
Peter A. McCullough ◽  
...  
Keyword(s):  
Heart Failure ◽  
Serum Potassium ◽  
Controlled Trial ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Heart Failure Patients ◽  
Sodium Zirconium ◽  
Sodium Zirconium Cyclosilicate

Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure

2015 ◽  
Vol 21 (8) ◽  
pp. S106
Author(s):  
Prakash Deedwania ◽  
Ileana L. Piña ◽  
Henrik S. Rasmussen ◽  
Philip T. Lavin ◽  
Bhupinder Singh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Serum Potassium ◽  
Sodium Zirconium ◽  
Patients With Heart Failure ◽  
Sodium Zirconium Cyclosilicate

scholarly journals Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia

2021 ◽  
Vol 60 (13) ◽  
pp. 2093-2095
Author(s):  
Teruhiko Imamura ◽  
Akira Oshima ◽  
Nikhil Narang ◽  
Ryuichi Ushijima ◽  
Yohei Ueno ◽  
...  
Keyword(s):  
Heart Failure ◽  
Combination Therapy ◽  
Receptor Antagonist ◽  
Mineralocorticoid Receptor ◽  
Mineralocorticoid Receptor Antagonist ◽  
Sodium Zirconium ◽  
Patients With Heart Failure ◽  
Sodium Zirconium Cyclosilicate

scholarly journals Use of sodium zirconium cyclosilicate for up-titration of renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure: a case series

2021 ◽  
Vol 5 (8) ◽  
Author(s):  
Rhys Williams ◽  
Alexander James ◽  
Moira Ashton ◽  
Sian Vaughan ◽  
Aaron Wong
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Case Series ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Additional Patient ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Sodium Zirconium ◽  
Sodium Zirconium Cyclosilicate

Abstract Background Patients often receive suboptimal dosing of renin–angiotensin–aldosterone system inhibitor (RAASi) therapy over concerns of hyperkalaemia. However, studies have shown associations between suboptimal dosing or interruptions to therapy and adverse clinical events. Therefore, effective treatments for hyperkalaemia that can enable optimal RAASi therapy are needed. This case series examines eight patients whose commencement on the novel potassium binder sodium zirconium cyclosilicate (SZC) allowed for the initiation and/or up-titration of RAASi therapy. Case summary Eight patients aged 64–87 years with heart failure (HF) with reduced ejection fraction all developed hyperkalaemia (serum potassium (sK+) >5.0 mmol/L) while receiving RAASi therapy. Following initiation of SZC, all patients experienced eventual stabilization of sK+ levels. All patients were able to initiate, restart, or up-titrate RAASi therapy with five patients achieving optimal medical therapy. Left ventricular ejection fraction improved in four patients, two patients are now re-classified as New York Heart Association Class I, and an additional patient had improved exercise tolerance. Follow-up for Patient 8 is still ongoing. Discussion These real-world cases demonstrate that use of SZC to manage hyperkalaemia in patients with HF is feasible and allows optimization of RAASi therapy.

Sign in / Sign up

Export Citation Format

Share Document